Riskpilot← Back to searchSign inGet full accessAH DIAGNOSTICS AS
ASActiveOrg 998509009Sandakerveien 138, 0484 OsloWholesale of pharmaceutical and medical goods · NACE 4646Est. 20120 employeeswww.diuvita.no
Revenue 2023
NOK 2,4M
-64% vs 2022
EBITDA margin
6.8%
-83% vs 2022
Equity ratio
97.5%
Financial strength
Net profit 2023
NOK 107K
-85% vs 2022
| Revenue | NOK 2,4M | -64% |
| EBITDA | NOK 161K | -83% |
| Net profit | NOK 107K | -85% |
| Total assets | NOK 1,5M | -18% |
| Equity | NOK 1,4M | +8% |
| Employees | 0 | — |
Legal name
AH DIAGNOSTICS AS
Org number
998509009
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
20. juni 2012
Share capital
NOK 120 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2023-12-31
Financial year
January – December
Signatory rights
Styrets leder alene. Daglig leder alene.
Company purpose
Import/eksport, salg av handelsvarer til sykehus, apotek og helserelaterte sportsartikler til forbrukere og videreforhandlere.
Address
Sandakerveien 138, 0484 Oslo
Website
www.diuvita.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 843 | 887 | 1 378 | 4 020 | 4 574 | 5 204 | 6 185 | 6 477 | 2 351 |
| Staff expenses | −0 | −0 | −0 | −1 | −1 | −200 | −688 | −806 | −1 078 | −893 | −664 | −11 |
| EBITDA | 0 | 0 | −105 | 146 | 134 | −178 | 423 | 272 | 372 | 1 083 | 933 | 161 |
| Depreciation & amort. | −0 | −0 | −0 | −10 | −41 | −3 | −7 | −7 | −4 | −3 | −14 | −14 |
| EBIT | 0 | 0 | −105 | 136 | 93 | −181 | 416 | 265 | 368 | 1 080 | 919 | 147 |
| Net financials | 0 | 0 | −0 | −12 | −14 | −23 | −15 | −17 | −2 | 38 | −14 | −8 |
| Profit before tax | 0 | 0 | −105 | 124 | 80 | −204 | 402 | 248 | 366 | 1 118 | 905 | 138 |
| Tax | −0 | −0 | −0 | 11 | 20 | −3 | 50 | 59 | 77 | 239 | 201 | 31 |
| Net profit | 0 | 0 | −105 | 113 | 60 | −201 | 352 | 189 | 289 | 879 | 704 | 107 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 30 | 30 | 96 | 470 | 340 | 301 | 1 104 | 1 124 | 1 153 | 2 588 | 1 794 | 1 475 |
| Equity | 30 | 30 | 15 | 128 | 188 | −13 | 339 | 328 | 617 | 626 | 1 331 | 1 438 |
| Long-term debt | 0 | 0 | 0 | 7 | 3 | 0 | 2 | 1 | 0 | 2 | 1 | 0 |
| Short-term debt | 0 | 0 | 81 | 335 | 149 | 314 | 763 | 795 | 536 | 1 959 | 463 | 37 |
| Total debt | 0 | 0 | 81 | 341 | 152 | 314 | 765 | 796 | 536 | 1 961 | 464 | 37 |
EBITDA margin
6.8%
This company
15.8%
Market median
-57% vs market
20122023
Equity ratio
97.5%
This company
38.2%
Market median
+155% vs market
20122023
Return on equity
7.5%
This company
18.4%
Market median
-59% vs market
20122023
Net profit margin
4.6%
This company
8.1%
Market median
-43% vs market
20122023
Asset turnover
1.59×
This company
1.12×
Market median
+42% vs market
20122023
Debt / equity
0.03×
This company
0.62×
Market median
+95% vs market
20122023
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via Brønnøysundsregistrene · Period 2012-05-28 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AS Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2014 | — | — | |
| Board of Directors | 2014 | — | — | |
| Deputy Chairman | 2014 | — | — | |
| Board of Directors | 2014 | — | — | |
| Chairman | 2014 | — | — | |
| Board of Directors | 2022 | — | — | |
| Chairman | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Ah Diagnostics A/S | Company | 100.0% | 100.0% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of AH DIAGNOSTICS AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anne Sofie Velo | Chief Executive Officer | 0 companies |
| Eirik Hemsborg Skar | Board of Directors | 0 companies |
| Morten Hemsborg Skar | Board of Directors | 0 companies |
| Per Willy Skar | Deputy Chairman | 0 companies |
| Ole Martin Hemsborg Skar | Board of Directors | 0 companies |
| Bente Hemsborg Skar | Chairman | 0 companies |
| Helle Vibeke Zacho | Board of Directors | 0 companies |
| Niels Stampe Rüdiger | Chairman | 0 companies |